PE20091394A1 - Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide - Google Patents

Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide

Info

Publication number
PE20091394A1
PE20091394A1 PE2008001866A PE2008001866A PE20091394A1 PE 20091394 A1 PE20091394 A1 PE 20091394A1 PE 2008001866 A PE2008001866 A PE 2008001866A PE 2008001866 A PE2008001866 A PE 2008001866A PE 20091394 A1 PE20091394 A1 PE 20091394A1
Authority
PE
Peru
Prior art keywords
compound
inhibitor
production
amyloid peptide
beta amyloid
Prior art date
Application number
PE2008001866A
Other languages
English (en)
Inventor
John E Starrett Jr
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20091394A1 publication Critical patent/PE20091394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA AL COMPUESTO (2R)-2-[[(4-CLOROFENIL)SULFONIL][[2-FLUORO-4-(1,2,4-OXADIAZOL-3-IL)FENIL]METIL]AMINO]-5,5,5-TRIFLUOROPENTANAMIDA. SE REFIERE TAMBIEN A SU PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. DICHO COMPUESTO ES INHIBIDOR DE LA PRODUCCION DE PEPTIDO BETA AMILOIDE, SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN, DETERIORO COGNITIVO BREVE, ENTRE OTROS
PE2008001866A 2007-10-31 2008-10-31 Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide PE20091394A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31

Publications (1)

Publication Number Publication Date
PE20091394A1 true PE20091394A1 (es) 2009-09-25

Family

ID=40193955

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001866A PE20091394A1 (es) 2007-10-31 2008-10-31 Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide

Country Status (29)

Country Link
US (2) US8084477B2 (es)
EP (3) EP2471769A1 (es)
JP (1) JP5460605B2 (es)
KR (1) KR20100075575A (es)
CN (2) CN102718689A (es)
AR (1) AR069135A1 (es)
AT (1) ATE502022T1 (es)
AU (1) AU2008319122A1 (es)
BR (1) BRPI0818837A2 (es)
CA (1) CA2704360A1 (es)
CL (1) CL2008003271A1 (es)
CO (1) CO6270332A2 (es)
CY (2) CY1112337T1 (es)
DE (1) DE602008005636D1 (es)
DK (2) DK2295417T3 (es)
EA (2) EA201171439A1 (es)
ES (2) ES2390042T3 (es)
HK (2) HK1141801A1 (es)
HR (2) HRP20110219T1 (es)
IL (1) IL205406A0 (es)
MX (1) MX2010004319A (es)
NZ (1) NZ584545A (es)
PE (1) PE20091394A1 (es)
PL (2) PL2295417T3 (es)
PT (2) PT2295417E (es)
SG (2) SG174044A1 (es)
SI (2) SI2295417T1 (es)
TW (1) TW200927099A (es)
WO (1) WO2009058552A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204281B1 (pl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Pochodna α-(N-sulfonamido)-acetamidu jako inhibitor ß-amyloidu oraz kompozycja farmaceutyczna
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
AU2009342632A1 (en) * 2009-03-19 2011-09-01 Bristol-Myers Squibb Company A novel alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
KR101409137B1 (ko) 2010-03-12 2014-06-17 닛뽕소다 가부시키가이샤 피리딘 고리 함유 화합물, 및 할로겐화피콜린 유도체 및 테트라졸릴옥심 유도체의 제조 방법
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
JP2013542973A (ja) * 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
CN114286828A (zh) 2019-06-24 2022-04-05 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
SK282833B6 (sk) 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
EP0939629A4 (en) 1996-07-22 2002-07-17 Monsanto Co THIOL-SULFONAMIDES AS METALLOPROTEINAS INHIBITORS
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
CN1224612C (zh) 1999-01-27 2005-10-26 惠氏控股有限公司 炔基磺酰胺硫醇tace抑制剂
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
KR20020006626A (ko) * 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
WO2003052481A2 (en) * 2001-12-14 2003-06-26 Raytheon Company Precisely aligned lens structure and a method for its fabrication
PL204281B1 (pl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Pochodna α-(N-sulfonamido)-acetamidu jako inhibitor ß-amyloidu oraz kompozycja farmaceutyczna
PL372090A1 (en) * 2002-02-28 2005-07-11 Astrazeneca Ab Chemical compounds
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
US7300951B2 (en) 2003-03-31 2007-11-27 Wyeth Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
CN101415670A (zh) 2006-02-17 2009-04-22 惠氏公司 制备磺酰胺取代醇和其中间体的方法
PE20080109A1 (es) 2006-02-17 2008-04-01 Wyeth Corp N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
SG174043A1 (en) 2011-09-29
SI2205575T1 (sl) 2011-07-29
JP5460605B2 (ja) 2014-04-02
EP2295417A1 (en) 2011-03-16
EP2205575B1 (en) 2011-03-16
PL2295417T3 (pl) 2012-11-30
JP2011502153A (ja) 2011-01-20
SI2295417T1 (sl) 2012-11-30
CO6270332A2 (es) 2011-04-20
EA201000714A1 (ru) 2010-10-29
EA016447B1 (ru) 2012-05-30
CN101910141B (zh) 2012-12-19
CN102718689A (zh) 2012-10-10
CA2704360A1 (en) 2009-05-07
EP2205575A1 (en) 2010-07-14
US8350084B2 (en) 2013-01-08
CY1113346T1 (el) 2016-06-22
EA201171439A1 (ru) 2012-05-30
TW200927099A (en) 2009-07-01
ES2361283T3 (es) 2011-06-15
SG174044A1 (en) 2011-09-29
EP2471769A1 (en) 2012-07-04
ATE502022T1 (de) 2011-04-15
AU2008319122A1 (en) 2009-05-07
HK1141801A1 (en) 2010-11-19
IL205406A0 (en) 2010-12-30
HRP20110219T1 (hr) 2011-04-30
PL2205575T3 (pl) 2011-09-30
BRPI0818837A2 (pt) 2015-04-22
CL2008003271A1 (es) 2009-07-10
HRP20120703T1 (hr) 2012-09-30
PT2205575E (pt) 2011-05-23
CN101910141A (zh) 2010-12-08
HK1155161A1 (en) 2012-05-11
MX2010004319A (es) 2010-04-30
WO2009058552A1 (en) 2009-05-07
KR20100075575A (ko) 2010-07-02
NZ584545A (en) 2011-04-29
DK2205575T3 (da) 2011-07-11
PT2295417E (pt) 2012-09-26
US20120088925A1 (en) 2012-04-12
ES2390042T3 (es) 2012-11-06
DE602008005636D1 (de) 2011-04-28
US8084477B2 (en) 2011-12-27
AR069135A1 (es) 2009-12-30
DK2295417T3 (da) 2012-10-15
CY1112337T1 (el) 2015-12-09
US20090111858A1 (en) 2009-04-30
EP2295417B1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
CL2007003583A1 (es) Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
CL2007001090A1 (es) Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras
EA200702483A1 (ru) Фармацевтическая композиция и её применение
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2008001157A1 (es) Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio.
CL2007002169A1 (es) Compuestos derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso del compuesto para prevenir o tratar la inflamacion, trastornos urologicos, gastrointestina
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0610132B8 (pt) composição farmacêutica, kit e utilização de uma composição
CL2007002511A1 (es) Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune.
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
AR076306A1 (es) Composiciones biodisponibles de compuestos alfa -(n-sulfonamido) acetamida amorfo
EA201171143A1 (ru) Новое соединение альфа-(n-сульфонамидо)ацетамида в качестве ингибитора продукции бета амилоидного пептида

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed